Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q3

2342.TEDINET S100Q04J
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 35
MetricValuePeriodScopeSource row
Revenue¥8.5bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥12.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥153m2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥1.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥385m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.7bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥344m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥1.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥182m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.9bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥803m2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥171m2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥795m2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥10.9bnat 2022-12-31Cons.Assets
Total assets¥10.4bnat 2022-03-31Cons.Assets
Total assets¥10.2bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥4.2bnat 2022-12-31Cons.Liabilities
Total liabilities¥3.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.6bnat 2022-03-31Cons.Net assets
Net assets / equity¥5.6bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥4.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥10.812022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥7.542022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥109.522021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.572021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-10.552021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥109.312021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥46.462021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio60.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.7%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥4m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥2m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥157m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥132m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥179m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥310m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥9m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥9m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥138m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥3.9bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.9bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥9m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥5.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥5.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥491,000
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥203m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥9.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥9m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 368
ItemContextValueUnit
Valuation and translation adjustmentsPrior1YearInstant15918000JPY
Valuation and translation adjustmentsCurrentQuarterInstant16277000JPY
Subscription rights to sharesPrior1YearInstant200000JPY
Subscription rights to sharesCurrentQuarterInstant200000JPY
Non controlling interestsPrior1YearInstant104007000JPY
Non controlling interestsCurrentQuarterInstant123724000JPY
Net assetsPrior1YearInstant6636782000JPY
Net assetsCurrentQuarterInstant6731456000JPY
Liabilities and net assetsPrior1YearInstant10440710000JPY
Liabilities and net assetsCurrentQuarterInstant10930603000JPY
Net salesPrior1YTDDuration9645084000JPY
Net salesCurrentYTDDuration8464143000JPY
Cost of salesPrior1YTDDuration6417579000JPY
Cost of salesCurrentYTDDuration6826411000JPY
Gross profitPrior1YTDDuration3227505000JPY
Gross profitCurrentYTDDuration1637731000JPY
Selling general and administrative expensesPrior1YTDDuration1494055000JPY
Selling general and administrative expensesCurrentYTDDuration1484425000JPY
Operating incomePrior1YTDDuration1733450000JPY
Operating incomeCurrentYTDDuration153305000JPY
Interest income noiPrior1YTDDuration697000JPY
Interest income noiCurrentYTDDuration420000JPY
Insurance income noiPrior1YTDDuration7462000JPY
Insurance income noiCurrentYTDDuration3214000JPY
Insurance premiums refunded cancellation noiPrior1YTDDuration31991000JPY
Insurance premiums refunded cancellation noiCurrentYTDDuration367498000JPY
Other noiPrior1YTDDuration7602000JPY
Other noiCurrentYTDDuration10909000JPY
Non operating incomePrior1YTDDuration47754000JPY
Non operating incomeCurrentYTDDuration382043000JPY
Interest expenses noePrior1YTDDuration16334000JPY
Interest expenses noeCurrentYTDDuration20094000JPY
Foreign exchange losses noePrior1YTDDuration4877000JPY
Foreign exchange losses noeCurrentYTDDuration19316000JPY
Acquisition expenses noePrior1YTDDuration38092000JPY
Acquisition expenses noeCurrentYTDDuration81000000JPY
Other noePrior1YTDDuration30037000JPY
Other noeCurrentYTDDuration29966000JPY
Non operating expensesPrior1YTDDuration89341000JPY
Non operating expensesCurrentYTDDuration150378000JPY
Ordinary incomePrior1YTDDuration1691863000JPY
Ordinary incomeCurrentYTDDuration384970000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration10954000JPY
Subsidy eiPrior1YTDDuration288951000JPY
Subsidy eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration288951000JPY
Extraordinary incomeCurrentYTDDuration10954000JPY
Impairment loss elPrior1YTDDuration169375000JPY
Impairment loss elCurrentYTDDuration47756000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass